» Articles » PMID: 12581747

Co-delivery of IL-2 or Liposomes Augment the Responses of Mice to a DNA Vaccine for Pseudorabies Virus IE180

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Recently we have demonstrated, with a DNA vaccine, that the immediate early protein (IE180) of pseudorabies virus provides a moderate level of protection in mice. In order to improve its immunogenicity and protective capacity, this IE180 DNA vaccine was delivered to C3H/HeJ mice either in combination with an IL-2 expressing plasmid or complexed with cationic liposomes. Co-delivery of the vaccine and IL-2 DNA by gene gun resulted in seroconversion in 5/5 of the vaccinated mice after a single administration, whereas two intramuscular (i.m.) injections were required to achieve seroconversion in all mice. Antibody and delayed-type hypersensitivity responses were augmented in mice, which received the DNA vaccine and the IL-2 gene compared to those of mice receiving the DNA vaccine alone. In addition, the time of death after challenge was significantly delayed in mice, which received the IL-2 gene. The proportion of surviving mice (40%), however, was similar to that obtained in mice which received the vaccine alone by gene gun. Liposome-mediated vaccine delivery also resulted in a higher rate of seroconversion when compared with that induced by the naked DNA vaccine. Thus, all vaccinated mice seroconverted after either two i.v. or three i.m. injections of the liposome/DNA complex, with 40 and 25% of these mice being protected against challenge, respectively. These data support that co-administration of the IE180 DNA vaccine with the IL-2 gene or delivery in liposomes are two effective approaches to increase its immunogenicity.

Citing Articles

A PRRSV GP5-Mosaic vaccine: Protection of pigs from challenge and ex vivo detection of IFNγ responses against several genotype 2 strains.

Cui J, OConnell C, Costa A, Pan Y, Smyth J, Verardi P PLoS One. 2019; 14(1):e0208801.

PMID: 30703122 PMC: 6354972. DOI: 10.1371/journal.pone.0208801.


Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.

Xu Y, Yuen P, Lam J Pharmaceutics. 2014; 6(3):378-415.

PMID: 25014738 PMC: 4190526. DOI: 10.3390/pharmaceutics6030378.


Materials innovation for co-delivery of diverse therapeutic cargos.

Godsey M, Suryaprakash S, Leong K RSC Adv. 2014; 3(47):24794-24811.

PMID: 24818000 PMC: 4012692. DOI: 10.1039/C3RA43094D.


Enhancement of the immunogenicity of an infectious bronchitis virus DNA vaccine by a bicistronic plasmid encoding nucleocapsid protein and interleukin-2.

Tang M, Wang H, Zhou S, Tian G J Virol Methods. 2008; 149(1):42-8.

PMID: 18329109 PMC: 7119663. DOI: 10.1016/j.jviromet.2008.01.017.